Nitrong (Glyceryl Trinitrate)

Glyceryl trinitrate is a nitric‑oxide donor. After the transdermal patch releases the drug, it is converted to nitric oxide, which activates soluble guanylate cyclase in vascular smooth‑muscle cells. This raises cyclic GMP levels, causing smooth‑muscle relaxation, vasodilation, and a reduction in myocardial oxygen consumption.

The prescribed dose of Nitrong is determined by the treating physician based on the individual’s clinical condition, severity of angina, and response to therapy. The prescriber selects the appropriate patch strength and duration of use, and patients should follow the specific instructions provided on the prescription label.

The safety of Nitrong during pregnancy and lactation has not been definitively established, and the pregnancy category is listed as unknown. Healthcare providers should weigh potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing individuals.

To order Nitrong, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Nitrong delivers glyceryl trinitrate via a transdermal patch, offering continuous nitric‑oxide release, which can provide more stable plasma levels than short‑acting oral nitrates. Compared with oral agents, the patch reduces dosing frequency and may improve adherence, but it shares similar vasodilatory side‑effects and contraindications.

Store Nitrong patches at room temperature, below 25 °C, in their original packaging. Keep them away from moisture, direct sunlight, and sources of heat. Do not expose the patches to extreme temperatures, and ensure they are kept out of reach of children.

Nitrong is applied to clean, dry, hair‑free skin on the upper torso or upper arm. The patch should be pressed firmly for several seconds to ensure adhesion, and the application site should be rotated to avoid skin irritation. The patch remains in place for the duration prescribed by the clinician.

The most serious risks include severe hypotension, which can cause fainting, and reflex tachycardia, a rapid heart rate that may compromise cardiac output. Rarely, methemoglobinemia can develop, impairing oxygen delivery. Patients should seek immediate medical attention if they experience dizziness, faintness, or any signs of an allergic reaction.

Nitrong should be avoided in patients with known hypersensitivity to glyceryl trinitrate or other nitrates, those who have taken phosphodiesterase‑5 inhibitors within the past 24‑48 hours, and individuals with severe anemia, increased intracranial pressure, or uncontrolled hypotension. Clinicians must evaluate each patient’s medical history before prescribing.